Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Abstract

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.

References 86

1. 1.
   SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma · 2021

   No notice
2. 2.

   Andreano E., Nicastri E., Paciello I., Pileri P., Manganaro N., Piccini G., Manenti A., Pantano E., Kabanova A., Troisi M. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021.

   Not in our library10.1016/j.cell.2021.02.035

3. 3.

   Aricescu A.R., Lu W., Jones E.Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 2006;62:1243-1250.

   Not in our library10.1107/s0907444906029799

4. 4.

   Avanzato V.A., Matson M.J., Seifert S.N., Pryce R., Williamson B.N., Anzick S.L., Barbian K., Judson S.D., Fischer E.R., Martens C. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183:1901-1912.e1909.

   Not in our library10.1016/j.cell.2020.10.049

5. 5.

   Barnes C.O., Jette C.A., Abernathy M.E., Dam K.A., Esswein S.R., Gristick H.B., Malyutin A.G., Sharaf N.G., Huey-Tubman K.E., Lee Y.E. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588:682-687.

   Not in our library10.1038/s41586-020-2852-1

6. 6.
   Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals · 2020

   No notice
7. 7.

   Bournazos S., Corti D., Virgin H.W., Ravetch J.V. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature. 2020;588:485-490.

   Not in our library10.1038/s41586-020-2838-z

8. 8.

   Briney B., Inderbitzin A., Joyce C., Burton D.R. Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature. 2019;566:393-397.

   Not in our library10.1038/s41586-019-0879-y

9. 9.

   Brochet X., Lefranc M.P., Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36:W503-8.

   Not in our library10.1093/nar/gkn316

10. 10.
    Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020

    No notice
11. 11.

    Carter M.J., Fish M., Jennings A., Doores K.J., Wellman P., Seow J., Acors S., Graham C., Timms E., Kenny J. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat. Med. 2020;26:1701-1707.

    Not in our library10.1038/s41591-020-1054-6

12. 12.

    Characterisation W.H.O.W.G.C., WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020;20:e192-e197.

    Not in our library10.1016/s1473-3099(20)30483-7

13. 13.

    Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021.

    Not in our library10.1038/s41591-021-01294-w

14. 14.
    A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020

    No notice
15. 15.

    Choi B., Choudhary M.C., Regan J., Sparks J.A., Padera R.F., Qiu X., Solomon I.H., Kuo H.H., Boucau J., Bowman K. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020;383:2291-2293.

    Not in our library10.1056/nejmc2031364

16. 16.
    Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies · 2021

    Corrected
17. 17.
    Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection · 2020

    No notice
18. 18.
    Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection · 2021

    No notice
19. 19.

    Dixon E.V. Mechanisms of immunoglobulin deactivation by Streptococcus pyogenes. 2014.

    Not in our library

20. 20.

    Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 2010;84:10510-10521.

    Not in our library10.1128/jvi.00552-10

21. 21.

    Doores K.J., Kong L., Krumm S.A., Le K.M., Sok D., Laserson U., Garces F., Poignard P., Wilson I.A., Burton D.R. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J. Virol. 2015;89:1105-1118.

    Not in our library10.1128/jvi.02905-14

22. 22.

    Edara V.V., Floyd K., Lai L., Gardner M., Hudson W., Piantadosi A., Waggoner J.J., Babiker A., Ahmed R., Xie X. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. 2021.

    Not in our library

23. 23.

    Greaney A.J., Loes A.N., Crawford K.H.D., Starr T.N., Malone K.D., Chu H.Y., Bloom J.D. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29:463-476.e6.

    Not in our library10.1016/j.chom.2021.02.003

24. 24.

    Grehan K., Ferrara F., Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX. 2015;2:379-384.

    Not in our library10.1016/j.mex.2015.09.003

25. 25.

    Gu Z., Eils R., Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847-2849.

    Not in our library10.1093/bioinformatics/btw313

26. 26.
    SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike · 2021

    Not checked
27. 27.

    Howarth M., Liu W., Puthenveetil S., Zheng Y., Marshall L.F., Schmidt M.M., Wittrup K.D., Bawendi M.G., Ting A.Y. Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat. Methods. 2008;5:397-399.

    Not in our library10.1038/nmeth.1206

28. 28.
    Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses · 2020

    Corrected
29. 29.

    Kemp S.A., Collier D.A., Datir R.P., Ferreira I.A.T.M., Gayed S., Jahun A., Hosmillo M., Rees-Spear C., Mlcochova P., Lumb I.U., CITIID-NIHR BioResource COVID-19 Collaboration, COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021.

    Not in our library10.1038/s41586-021-03291-y

30. 30.

    Kim S.I., Noh J., Kim S., Choi Y., Yoo D.K., Lee Y., Lee H., Jung J., Kang C.K., Song K.H. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. Sci. Transl. Med. 2021;13:eabd6990.

    Not in our library10.1126/scitranslmed.abd6990

31. 31.

    Laing A.G., Lorenc A., Del Molino Del Barrio I., Das A., Fish M., Monin L., Muñoz-Ruiz M., McKenzie D.R., Hayday T.S., Francos-Quijorna I. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 2020;26:1623-1635.

    Not in our library10.1038/s41591-020-1038-6

32. 32.
    A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity · 2021

    No notice
33. 33.

    Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H., Nie L. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020;182:1284-1294.e1289.

    Not in our library10.1016/j.cell.2020.07.012

34. 34.

    Li W., Chen C., Drelich A., Martinez D.R., Gralinski L.E., Sun Z., Schäfer A., Kulkarni S.S., Liu X., Leist S.R. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA. 2020;117:29832-29838.

    Not in our library10.1073/pnas.2010197117

35. 35.
    Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity · 2020

    No notice
36. 36.

    Liu L., Wang P., Nair M.S., Yu J., Rapp M., Wang Q., Luo Y., Chan J.F., Sahi V., Figueroa A. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450-456.

    Not in our library10.1038/s41586-020-2571-7

37. 37.

    Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

    Not in our library10.1016/s0140-6736(20)30251-8

38. 38.

    McCallum M., Marco A., Lempp F., Tortorici M.A., Pinto D., Walls A.C., Beltramello M., Chen A., Liu Z., Zatta F. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021.

    Not in our library10.1016/j.cell.2021.03.028

39. 39.
    Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape · 2021

    No notice
40. 40.

    Muecksch F., Wise H., Batchelor B., Squires M., Semple E., Richardson C., McGuire J., Clearly S., Furrie E., Greig N. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J. Infect. Dis. 2020.

    Not in our library10.1093/infdis/jiaa659

Cited by papers we hold 7

• Mutations and Evolution of the SARS-CoV-2 Spike Protein · 2022
  Corrected
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency · 2021
  Not checked
• A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants · 2021
  Not checked
• Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 · 2021
  No notice
• Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? · 2021
  No notice
• Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.